Roche’s Phase III study of using the combination of tiragolumab and tecentriq to treat a form of lung cancer did not achieve the desired success, the Swiss drugmaker said on Tuesday. The SKYSCRAPER-01 study ‘did not meet the primary endpoint of overall survival in the final analysis’ in patients with advanced or metastatic non-small cell lung cancer, it said.